Table 2.
Distribution of participants in each randomized dose group across strata of achieved serum 25(OH)D concentration
| 200 IU/d (N = 314) |
1000 IU/d (N = 195) |
2000 IU/d (N = 64) |
4000 IU/d (N = 64) |
|
|---|---|---|---|---|
| Level at 3 mo, ng/mL | ||||
| ≤ 29 | 214 (68.2%) | 67 (34.4%) | 15 (23.4%) | 3 (4.7%) |
| 30-39 | 96 (30.6%) | 101 (51.8%) | 33 (51.6%) | 12 (18.8%) |
| > 40 | 4 (1.3%) | 27 (13.8%) | 16 (25.0%) | 49 (76.6%) |
| Absolute change from BL to 3 mo (FU-BL, ng/mL) | ||||
| Lower 25%: -9 to 2 | 119 (37.9%) | 22 (11.3%) | 5 (7.8%) | 1 (1.6%) |
| Middle 50%: 3-14 | 179 (57.0%) | 129 (66.2%) | 33 (51.6%) | 9 (14.1%) |
| Upper 25%: 15-66 | 16 (5.1%) | 44 (22.6%) | 26 (40.6%) | 54 (84.4%) |
| Relative change from BL to 3 months ((FU-BL)/BL, (%)) | ||||
| Lower 25%: -36 to 10 | 127 (40.4%) | 26 (13.3%) | 5 (7.8%) | 1 (1.6%) |
| Middle 50%: 11-70 | 152 (48.4%) | 125 (64.1%) | 32 (50.0%) | 11 (17.2%) |
| Upper 75%: 71-455 | 35 (11.1%) | 44 (22.6%) | 27 (42.2%) | 52 (81.3%) |
To convert 25(OH)D ng/ml to nmol/L, multiply ng/mL by 2.5.
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BL, baseline; FU, follow-up.